Samrat Pharmachem Ltd.
BSE: SAMRATPH · Pharmaceuticals · sector
₹274.85BSE close 2026-10-26
Key numbers
Market cap₹85 cr
Price₹274.85
52w high / low₹310 / ₹190
P/E21.4xSector median 27.9x
P/B1.2xSector median 2.9x
Book value₹220.7
Dividend yield0.36%Sector median 0.48%
ROE-3.1%Sector median 11.7%
ROCE-1.2%Sector median 12.3%
OPM-0.5%Sector median 14.0%
Debt / equity0.16xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-1.5x
Current ratio1.86x
Sales growth 3y-2.3%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹6 cr vs borrowings ₹11 cr (FY26): borrowings are higher by ₹4 cr.
- Operating profit covered interest -1.5x in the last 12 months.
- Net loss in 5 of the last 6 quarters.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹274.85 on 2026-10-26: -11.3% from the 52-week high, +44.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹605.35 · low ₹197.90
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 71 | 76 | 79 | 63 | 72 | 80 |
| EBITDA | 0 | 0 | -0 | -1 | -1 | 1 |
| OPM % | 0.2% | 0.2% | -0.5% | -1.0% | -1.7% | 1.1% |
| Other income | -0 | 1 | 0 | 0 | -0 | 1 |
| Net profit | -0 | -0 | -1 | -0 | -2 | 1 |
| EPS (₹) | 1.29 | 0.74 | 1.90 | 1.49 | 6.59 | 2.84 |
| Revenue YoY | +0.8% | +5.4% | ||||
| Profit YoY | – | – |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 222 | 311 | 282 | 286 | 290 | 294 |
| EBITDA | 24 | 24 | 2 | 10 | -2 | -1 |
| Net profit | 17 | 17 | 2 | 7 | -3 | -2 |
| EPS (₹) | 55.62 | 53.83 | 7.00 | 23.02 | 10.72 | 12.82 |
| Revenue growth | +40.1% | -9.4% | +1.5% | +1.4% | – | |
| Profit growth | -3.3% | -87.0% | +229.2% | -146.6% | – | |
| Dividend / share (₹) | – | 1.00 | 1.00 | 1.00 | 1.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -2.3% | – | – |
| Net profit | – | – | – |
| EPS | -41.6% | – | – |
| Share price | – | -22.2% (2y) | -4.9% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 72 | 68 |
| Borrowings | 10 | 11 |
| Cash & equivalents | 1 | 6 |
| Total assets | 121 | 124 |
| Fixed assets | 10 | 12 |
| Capital work in progress | – | 1 |
| Investments | 3 | 4 |
| Receivables | 57 | 51 |
| Inventory | 38 | 44 |
| Payables | 39 | 43 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -10 | 9 |
| Cash from investing | 0 | -3 |
| Cash from financing | 0 | -0 |
| Capex | 0 | 3 |
| Free cash flow | -10 | 6 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 9.9% | -4.9% |
| ROCE % | 12.9% | -2.6% |
| Debtor days | 72 | 64 |
| Inventory days | 52 | 56 |
| Payable days | 53 | 55 |
| Cash conversion cycle (days) | 71 | 65 |
| Working capital days | 69 | 60 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SAMRATPH | ₹85 cr | 21.4x | 1.2x | -3.1% | -1.2% | -0.5% | -2.3% | 0.36% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2025-09-18 | Dividend | Final Dividend Rs 1.0 |
| 2024-09-19 | Dividend | Final Dividend Rs 1.0 |
| 2023-09-18 | Dividend | Dividend Rs 1.0 |
| 2022-09-22 | Dividend | Dividend Rs 1.0 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SAMRATPH |
| BSE code | 530125 |
| ISIN | INE103E01016 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.